PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY TYPE
PART 07: CUSTOMER LANDSCAPE
• Market segmentation by type
• Comparison by type
• Non-systemic antacids – Market size and forecast 2018-2023
• Systemic antacids – Market size and forecast 2018-2023
• Market opportunity by type
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas – Market size and forecast 2018-2023
• EMEA – Market size and forecast 2018-2023
• APAC – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
• PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Bayer
• GlaxoSmithKline
• Johnson & Johnson Services
• Novartis
• Sanofi
PART 14: APPENDIX
• Research methodology
• List of abbreviations
Exhibit 01: Years in consideration
Exhibit 02: Global GERD market
Exhibit 03: Segments of global GERD market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: Type – Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Non-systemic antacids – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Non-systemic antacids – Year-over-year growth 2019-2023 (%)
Exhibit 22: Systemic antacids – Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Systemic antacids – Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by type
Exhibit 25: Market share by geography 2018-2023 (%)
Exhibit 26: Geographic comparison
Exhibit 27: Americas – Market size and forecast 2018-2023 ($ millions)
Exhibit 28: Americas – Year-over-year growth 2019-2023 (%)
Exhibit 29: EMEA – Market size and forecast 2018-2023 ($ millions)
Exhibit 30: EMEA – Year-over-year growth 2019-2023 (%)
Exhibit 31: APAC – Market size and forecast 2018-2023 ($ millions)
Exhibit 32: APAC – Year-over-year growth 2019-2023 (%)
Exhibit 33: Key leading countries
Exhibit 34: Market opportunity
Exhibit 35: Decision framework
Exhibit 36: Global prevalence of geriatric population
Exhibit 37: Impact of drivers and challenges
Exhibit 38: Drugs that underwent prescription to OTC switch in US
Exhibit 39: Vendor landscape
Exhibit 40: Landscape disruption
Exhibit 41: Vendors covered
Exhibit 42: Vendor classification
Exhibit 43: Market positioning of vendors
Exhibit 44: Bayer – Vendor overview
Exhibit 45: Bayer – Business segments
Exhibit 46: Bayer – Organizational developments
Exhibit 47: Bayer – Geographic focus
Exhibit 48: Bayer – Segment focus
Exhibit 49: Bayer – Key offerings
Exhibit 50: Bayer – Key customers
Exhibit 51: GlaxoSmithKline – Vendor overview
Exhibit 52: GlaxoSmithKline – Business segments
Exhibit 53: GlaxoSmithKline – Organizational developments
Exhibit 54: GlaxoSmithKline – Geographic focus
Exhibit 55: GlaxoSmithKline – Segment focus
Exhibit 56: GlaxoSmithKline – Key offerings
Exhibit 57: GlaxoSmithKline – Key customers
Exhibit 58: Johnson & Johnson Services – Vendor overview
Exhibit 59: Johnson & Johnson Services – Business segments
Exhibit 60: Johnson & Johnson Services – Organizational developments
Exhibit 61: Johnson & Johnson Services – Geographic focus
Exhibit 62: Johnson & Johnson Services – Segment focus
Exhibit 63: Johnson & Johnson Services – Key offerings
Exhibit 64: Johnson & Johnson Services – Key customers
Exhibit 65: Novartis – Vendor overview
Exhibit 66: Novartis – Business segments
Exhibit 67: Novartis – Organizational developments
Exhibit 68: Novartis – Geographic focus
Exhibit 69: Novartis – Segment focus
Exhibit 70: Novartis – Key offerings
Exhibit 71: Novartis – Key customers
Exhibit 72: Sanofi – Vendor overview
Exhibit 73: Sanofi – Business segments
Exhibit 74: Sanofi – Organizational developments
Exhibit 75: Sanofi – Geographic focus
Exhibit 76: Sanofi – Segment focus
Exhibit 77: Sanofi – Key offerings
Exhibit 78: Sanofi – Key customers
Exhibit 79: Validation techniques employed for market sizing
Exhibit 80: List of abbreviations
【掲載企業】
Bayer、GlaxoSmithKline、Johnson & Johnson Services、Novartis、Sanofi